|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5453566A
(en)
|
1986-03-28 |
1995-09-26 |
Calgene, Inc. |
Antisense regulation of gene expression in plant/cells
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
MC2115A1
(fr)
|
1987-12-15 |
1991-07-05 |
Gene Shears Pty Ltd |
Ribozynes
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8822492D0
(en)
|
1988-09-24 |
1988-10-26 |
Considine J |
Apparatus for removing tumours from hollow organs of body
|
|
US5211657A
(en)
|
1988-11-07 |
1993-05-18 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
|
EP0438803B1
(en)
|
1990-01-26 |
1997-03-12 |
Immunomedics, Inc. |
Vaccines against cancer and infectious diseases
|
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
|
US5789573A
(en)
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
|
IL108367A0
(en)
|
1993-01-27 |
1994-04-12 |
Hektoen Inst For Medical Resea |
Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
|
|
SE9301911D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptide derivatives
|
|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
|
IL112795A
(en)
|
1994-03-04 |
2001-01-28 |
Astrazeneca Ab |
Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
|
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US6011158A
(en)
|
1994-12-13 |
2000-01-04 |
Corvas International, Inc. |
Aromatic heterocyclic derivatives as enzyme inhibitors
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
|
US5866573A
(en)
|
1997-04-21 |
1999-02-02 |
Merck & Co., Inc. |
Pyrazinone thrombin inhibitors
|
|
AU742178B2
(en)
*
|
1998-05-26 |
2001-12-20 |
Merck & Co., Inc. |
Imidazopyridine thrombin inhibitors
|
|
WO2000026211A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck & Co., Inc. |
Thrombin inhibitors
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
|
BR0010758A
(pt)
*
|
1999-05-19 |
2003-06-10 |
Pharmacia Corp |
Aril e heteroaril pirimidinonas policìclicas substituìdas úteis como anti coagulantes
|
|
US6664255B1
(en)
|
1999-05-19 |
2003-12-16 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
|
|
CZ20014115A3
(cs)
*
|
1999-05-19 |
2002-05-15 |
Pharmacia Corporation |
Substituované polycyklické aryl a heteroaryl pyrazinony vhodné pro selektivní inhibici koagulační kaskády
|
|
NZ514877A
(en)
*
|
1999-05-19 |
2004-10-29 |
Pharmacia Corp |
Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
|
|
US7015230B1
(en)
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
|
US6653316B1
(en)
*
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
US20040072862A1
(en)
|
1999-06-04 |
2004-04-15 |
Bitler Catherine M. |
Compositions for treating ischemia-related neuronal damage
|
|
US6649592B1
(en)
|
2000-01-14 |
2003-11-18 |
Science & Technology Corporation @ Unm |
Peptide inhibitors of LFA-1/ICAM-1 interaction
|
|
WO2001079195A2
(en)
|
2000-04-14 |
2001-10-25 |
Corvas International, Inc. |
Pyridine and pyrazine derivatives as thrombin inhibitors
|
|
WO2001087851A1
(en)
*
|
2000-05-18 |
2001-11-22 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
|
AU2002230836A1
(en)
|
2000-12-18 |
2002-07-01 |
Merck & Co., Inc. |
Benzylamine derivatives and their use as thrombin inhibitors
|
|
MXPA04003167A
(es)
*
|
2001-10-03 |
2004-07-08 |
Pharmacia Corp |
Compuestos heterociclicos insaturados de 6 miembros utiles para la inhibicion selectiva de la cascada de coagulacion.
|
|
JP2005509606A
(ja)
*
|
2001-10-03 |
2005-04-14 |
ファルマシア・コーポレーション |
凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ
|
|
ES2601143T3
(es)
|
2002-07-19 |
2017-02-14 |
Omeros Corporation |
Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
|
|
WO2004032834A2
(en)
|
2002-10-04 |
2004-04-22 |
Merck & Co., Inc. |
Thrombin inhibitors
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
|
ES2631127T3
(es)
|
2004-06-10 |
2017-08-28 |
Omeros Corporation |
Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
|
|
KR20080002832A
(ko)
*
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
DK2488203T3
(en)
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
HUP1000366A2
(en)
|
2010-07-13 |
2012-03-28 |
Mta Enzimologiai Intezet |
Novel proteins, their production process and use tereof
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
BR112013025917A2
(pt)
|
2011-04-08 |
2016-12-20 |
Omeros Corp |
uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
|
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
|
AU2013201779B2
(en)
|
2011-05-04 |
2016-01-07 |
Omeros Corporation |
Compositions for inhibiting MASP-2 dependent complement activation
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
MX357540B
(es)
|
2012-04-06 |
2018-07-13 |
Omeros Corp |
Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
|
|
BR112014031522A2
(pt)
|
2012-06-18 |
2017-08-01 |
Omeros Corp |
métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
|
|
AR091490A1
(es)
|
2012-06-19 |
2015-02-11 |
Bristol Myers Squibb Co |
Antagonistas de iap
|
|
EP2906236A1
(en)
|
2012-10-10 |
2015-08-19 |
Novo Nordisk Health Care AG |
Liquid pharmaceutical composition of factor vii polypeptide
|
|
EP2922535B1
(en)
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
|
JP2016539919A
(ja)
|
2013-10-17 |
2016-12-22 |
オメロス コーポレーション |
Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
|
|
CA2935683A1
(en)
|
2013-12-30 |
2015-07-09 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
AU2016354117B2
(en)
|
2015-11-09 |
2019-11-28 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR102528260B1
(ko)
|
2016-01-05 |
2023-05-04 |
유니버시티 오브 레스터 |
필요로 하는 대상체에서 섬유증의 억제 방법
|
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
MX2018011648A
(es)
|
2016-03-31 |
2019-01-30 |
Omeros Corp |
Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
TWI881481B
(zh)
|
2017-08-15 |
2025-04-21 |
美商歐米諾斯公司 |
用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
|
|
PE20200924A1
(es)
|
2017-09-13 |
2020-09-14 |
Amgen Inc |
Compuestos de bisamida sustituida que activan el sarcomero cardiaco
|
|
GB201805174D0
(en)
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
IL311042B1
(en)
|
2018-05-29 |
2026-04-01 |
Omeros Corp |
MASP-2 inhibitors and methods of use
|
|
EP4069678A1
(en)
|
2019-12-04 |
2022-10-12 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
EP4069676A1
(en)
|
2019-12-04 |
2022-10-12 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
BR112022010895A2
(pt)
|
2019-12-04 |
2022-09-06 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
|
|
WO2022035997A1
(en)
|
2020-08-11 |
2022-02-17 |
Avilar Therapeutics, Inc. |
In vivo assembly of asgpr binding therapeutics
|